The board of directors of the Swiss Galenica Group has designated Stef Savean Schulze, currently chief executive of group company Vifor Fresenius Medical Care Renal Pharma (VFMCRP), as chief operating officer and president of the executive committee of Vifor Pharma.
Under the proven leadership of the executive chairman of the board, Etienne Jornod, Stefan Schulze will take over this position from the Annual General Meeting of Galenica in May 2017.
Until the 2017 AGM, Gianni Zampieri will remain responsible for the operational management of Vifor Pharma and will gradually introduce Stefan Schulze to the various duties and responsibilities. In parallel, Stefan Schulze will look for his successor as CEO of VFMCRP. At the next Annual General Meeting, Gianni Zampieri will be proposed to shareholders for election to the board of directors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze